key: cord-0833203-g9d008fe
authors: Cheon, Shinhye; Park, Uni; Park, Hyoree; Kim, Yuri; Hai Nguyen, Yen Thi; Aigerim, Abdimadiyeva; Rhee, Ji-Young; Choi, Jae-Phil; Park, Wan Beom; Park, Sang Won; Kim, Yeonjae; Lim, Dong-Gyun; Yang, Jeong-Sun; Lee, Joo-Yeon; Kim, Yeon-Sook; Cho, Nam-Hyuk
title: Longevity of seropositivity and neutralizing antibodies in recovered MERS patients: a five-year follow-up study
date: 2021-06-14
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.06.009
sha: 29817d18949df780ffd8b295fd4e04696dd14389
doc_id: 833203
cord_uid: g9d008fe

OBJECTIVES: We aimed to assess the longevity of spike-specific antibody responses and neutralizing activity in the plasma of recovered Middle East respiratory syndrome (MERS) patients. METHODS: We traced the antibody responses and neutralizing activity against MERS coronavirus (MERS-CoV) in peripheral blood samples collected from 70 recovered MERS patients for five years after the 2015 MERS outbreak in South Korea. We also measured the half-life of neutralizing antibody titers in the longitudinal specimens. RESULTS: The seropositivity rate persisted for up to four years (50.7–56.1%), especially in MERS patients who suffered from severe pneumonia, and then decreased (35.9%) in the fifth year. Although the spike-specific antibody responses decreased gradually, the neutralizing antibody titers decreased more rapidly (half-life: 20 months) in 19 participants without showing negative seroconversion during the study period. Only five (26.3%) participants had neutralizing antibody titers greater than 1/1,000 of PRNT(50), and a high neutralizing antibody titer over 1/5,000 was not detected in the participants at five years after infection. CONCLUSIONS: The seropositivity rate of the recovered MERS patients persisted up to four years after infection and significantly dropped in the fifth year, whereas the neutralizing antibody titers against MERS-CoV decreased more rapidly and were significantly reduced at four years after infection.

Newly emerging zoonotic coronaviruses, which cause acute respiratory syndrome, have posed enormous threats 72 to global public health within just two decades [1] . Severe acute respiratory syndrome coronavirus (SARS-CoV) 73

and Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in China in 2002 and the Middle East 74 in 2012, respectively; these viruses have resulted in 11% and 35% of deaths, respectively [1, 2] . The third 75 zoonotic coronavirus, SARS-CoV-2, has been spreading at an alarming rate worldwide since December 2019, 76 with a mortality rate of approximately 2.0% (https://covid19.who.int). Despite the catastrophic impact of 77 coronaviruses on public health worldwide, few effective therapeutic options are available for the diseases caused 78 by these viruses [3] . Immune serum or plasma samples collected from recovered patients have been found to 79 retain neutralizing activity in clinical therapeutic applications [4] [5] [6] [7] . However, knowledge of the long-term 80 dynamics and durability of specific antibody responses in recovered MERS and COVID-19 patients is limited. 

In total, 70 recovered MERS patients were recruited in the present study; their baseline characteristics are 94 summarized in Supplementary Table S1 and can also be found in our previous report [7] . All the participants 95 were confirmed to be positive for MERS-CoV infection by a real-time RT-PCR assay targeting the upE and 96 orf1a sequences of the virus at a diagnostic laboratory in the Korean Center for Disease Control. During the 97 study period, 31 participants were lost to follow-up, leaving 39 participants at 60 months. Serum samples were 98 collected from the participants at 12-month intervals after symptom onset. Data for the first three years were 99 assessed in our previous study [7] and have been included in this research. Ethical approval for using the 100 participants' clinical data and specimens was obtained from the institutional review boards of Chungnam 

To detect the levels of MERS-CoV spike (S1 domain)-specific IgGs, semi-quantitative ELISA was performed 109

using an anti-MERS-CoV S1 ELISA kit (EUROIMMUN, Lubeck, Germany) according to the manufacturer's 

Statistical analysis among different groups was performed using a two-tailed Student's t-test or one-way analysis 130 of variance (ANOVA), followed by the Newman-Keuls t-test. The correlation between variables was assessed 131 using the Pearson correlation test. p < 0.05 was considered statistically significant. All data analyses were 132 performed using GraphPad Prism Software. 133 134

The participants were classified into three groups according to their disease severity during the 2015 MERS 136 outbreak in Korea [7, 9] . Group I (G-I) included 18 participants who were asymptomatic or had mild fever 137 without developing pneumonia. Group II (G-II) included 33 participants who developed mild pneumonia 138 without hypoxemia. Group III (G-III) included 18 participants who recovered after developing more prolonged 139 and severe pneumonia. The participants in G-III experienced hypoxemia and were treated with oxygen during 140 hospitalization (Supplementary Table S1 ). 141

Humoral immune responses against the MERS-CoV spike antigen were assessed in all the serum samples 142 J o u r n a l P r e -p r o o f collected from the participants up to 60 months after symptom onset ( Figure 1A ). The geometric mean OD 143 ratios against the spike antigen (S1) were generally maintained for 48 months in all the samples analyzed 144

(geometric mean ± S.D.: 0.95 ± 1.17, 1.06 ± 1.52, 1.01 ± 1.42, and 1.15 ± 1.17 at 12, 24, 36, and 48 months, 145 respectively) and decreased thereafter (0.84 ± 1.02 at 60 months). The seropositivity rate also persisted for up to 146 48 months after infection (50.7%, 53.0%, 54.9%, and 56.1% at 12, 24, 36, and 48 months, respectively) and 147 decreased to 35.9% (14/39 participants) at 60 months ( Figure 1B ). The seropositivity rates were generally higher 148 in participants who had more severe disease, as reported previously [7] . In particular, no participant in G-I was 149

seropositive from 36 months after infection (Figure 1C ). In G-II, 54.6-65.0% of the participants were 150 persistently seropositive for up to 48 months, while 35.3% (6/17 participants) were seropositive at 60 months. In 816, respectively). Nevertheless, the neutralizing antibody titers were generally higher in patients with more 162 severe pneumonia (G-III) than in those with milder disease (G-II) (Figure 2A , right panels). In addition, the OD 163 ratios against the S1 antigen correlated well with the neutralizing antibody titers against MERS-CoV in the 164 plasma samples collected during the fourth and fifth years ( Figure 2B) . 165

We previously found that pulmonary viral loads and mortality were significantly reduced upon lethal MERS-166

CoV challenge in a transgenic mouse model therapeutically treated with human plasma containing a high 167 neutralizing antibody titer (PRNT 50 > 1/5,000); however, treatment with plasma containing a moderate In this five-year follow-up study, the characteristics and maintenance of humoral immunity against the MERS-180

CoV spike antigen were analyzed in 70 participants had recovered from MERS. In our previous study, we 181 confirmed that specific IgG responses, especially neutralizing antibody responses, were sustained for up to three 182 years after infection and that this was particularly noted in MERS patients who developed viral pneumonia [7] . 183

These findings are consistent with those of other tracer studies that were conducted with smaller sample sizes 184 and for shorter periods of less than three years after the initial MERS-CoV infection [10] [11] [12] . Sustained antibody 185 responses were found to be significantly associated with clinical severity and the duration of viral continuity 186 during the acute phase [9, 12-15]. We also confirmed the presence of significant correlations between the 187 antibody response levels and fever duration, viral shedding periods, and maximum viral loads [7] . In the present 188 study, we observed that the seropositivity rate persisted for up to four years after infection and dropped in the 189 fifth year (Figure 1 ). In contrast, the neutralizing antibody titers against MERS-CoV decreased more rapidly and points, statistical analysis was performed using one-way ANOVA, followed by the Newman-Keuls t-test. *, p < 349 0.05. B. Correlations of OD ratios against the S1 antigen with neutralizing antibody titers against MERS-CoV 350 (PRNT 50 ) were assessed using linear regression analysis (black line) with 95% confidence intervals (gray) and 351 the Pearson correlation test (coefficient and p value are presented). C. Kinetic changes in OD ratios against the 352 S1 antigen (blue) and neutralizing activity (PRNT 50 , red) in serum samples collected from 19 recovered MERS 353 patients without negative seroconversion during the study period. Linear regression analysis (solid line) with 354

SARS and MERS: recent insights into emerging

Middle East respiratory syndrome 233 coronavirus: risk factors and determinants of primary, household, and nosocomial transmission

Nucleoside analogues for the treatment of coronavirus infections, Current 236 opinion in virology

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection

Saudi Arabia

Challenges of convalescent 243 plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

Convalescent Plasma Study, The effectiveness of convalescent plasma and 247 hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a 248 systematic review and exploratory meta-analysis

Sustained responses of neutralizing 251 antibodies against MERS-CoV in recovered patients and their therapeutic applicability

A systematic review of antibody mediated immunity to 255 coronaviruses: kinetics, correlates of protection, and association with severity

Comparative and kinetic analysis of viral shedding and immunological 258 responses in MERS patients representing a broad spectrum of disease severity

Persistence of Antibodies against Middle East 261 Respiratory Syndrome Coronavirus

MERS-CoV Antibody Responses 1 Year after Symptom 264 Onset

Antibody Response and 267 Disease Severity in Healthcare Worker MERS Survivors

Kinetics of Serologic Responses to 270 MERS Coronavirus Infection in Humans

Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome 274 Coronavirus Infection

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory 281 syndrome: a six-year follow-up study

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Use of convalescent plasma therapy in SARS patients in Hong Kong

Experience of using convalescent plasma for severe acute respiratory syndrome 292 among healthcare workers in a Taiwan hospital

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Convalescent plasma as a potential therapy for COVID-19

Nature and 302 dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19, 303

Convalescent plasma for COVID-19 complicated by ARDS due to TRALI, 305

Landscape analysis of escape variants 308 identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Dissecting antibody-mediated protection against SARS-CoV-2

Feasibility, safety, clinical, and 315 laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome 316 coronavirus infection: a study protocol